中文 English

A new paradigm of mechanism- and patient-centered pharmaceutical research and development

New Mechanism, New Target Drug Pipelines

  • Disease
    Type of drug
    Project code
    Data-driven target discovery
    Target validation
    Drug synthesis
    Preclinical studies
    IND-enabling
  • Pancreatic cancer
    Small molecules
    ZY0001
  • Pan-cancer
    Biologics
    ZY0002
  • Pancreatic cancer
    Small molecules
    ZY0003

Drug Repurposing Pipelines

  • Drug field
    Project code
    Data-driven drug repurposing
    Biological evidence
    Clinical evidence
    Patent application
    Approved
  • CDK4/6 inhibitors
    ZYNI001
  • PARP inhibitors
    ZYNI002
  • Anti-tumor drugs
    ZYNI003
    Undisclosed
  • Anti-tumor drugs
    ZYNI004
    Undisclosed
  • Anti-tumor drugs
    ZYNI005
    Undisclosed

Precision Medical Products Pipelines

  • Disease
    Project
    Data-driven new insights
    Patent application
    Clinical trials registration
    Approved
    Marketing
  • Liver cancer
    Companion diagnostics
  • Breast cancer
    Precision pathological classification
  • Breast cancer
    Very early accurate diagnosis

Clinical Research Programs

  • Diseases
    Research direction
    Establishment of mechanistic models
    Clinical study design
    Patient recruitment
    Model adjustment and validation
    New scientific insights
    Patent application
    Model validation
    New pipeline development
  • Breast cancer
    Study on the pathogenesis of triple negative breast cancer based on germline genome
  • Liver cancer
    Establish the applicability method of HAI-FOLFOX in patients with liver cancer
  • Breast cancer
    Study on germline genomic etiology and early prevention of breast cancer
  • Pansolid tumor
    Clinical research on drug repurposing and companion diagnostics
  • Lung cancer
    Study the mechanism of brain metastasis of lung adenocarcinoma
  • Solid tumor
    Study the precise distribution mechanism of targeted drugs
  • Solid tumor
    Study the precise distribution mechanism of targeted drugs
  • 京ICP备17032047号© 2019 Phil Rivers Technology (Beijing) Ltd. All rights reserved
  • +86 10 6258 0703
    support@philrivers.com
  • ※   Room 314, Office of CHINA SCIENCE DAILY, B3 South No.1 Road, Zhongguancun, Haidian District, Beijing, China
    ※   Industrialization Complex Building,Rm B603-B604,Shenzhen Virtual University,Shenzhen,China
+86 10 6258 0703
support@philrivers.com
Room 314, Office of CHINA SCIENCE DAILY, B3 South No.1 Road, Zhongguancun, Haidian District, Beijing, China
Industrialization Complex Building,Rm B603-B604,Shenzhen Virtual University,Shenzhen,China
京ICP备17032047号 © 2019 Phil Rivers Technology (Beijing) Ltd. All rights reserved

扫一扫关注公众号